First-line icotinib versus cisplatine/pemetrexed plus pemetrexed maintenance therapy in lung adenocarcinoma patients with sensitizing EGFR mutation (CONVINCE).
机构：[1]Department of Medical Oncology, Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College[2]Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, Beijing, China[3]Department of Medical Oncology, Cancer Institute/Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China[4]Shanghai Chest Hospital, Shanghai, China[5]First Hospital Affiliated to Jilin University, Jilin, China[6]Department of Lung Cancer Medical Oncology, Sichuan Cancer Hospital, Chengdu, China四川省肿瘤医院[7]Department of Medical Oncology, the First Hospital of China Medical University, Shenyang, China[8]Tumor Hospital Of Hebei Province, Shijiazhuang, China河北医科大学第四医院[9]Shanxi Provincial Tumor Hospital, Taiyuan, China[10]Henan Cancer Hospital, Zhengzhou, China河南省肿瘤医院[11]Xijing Hospital, Xian, China[12]China Jinagsu Province Inst of Cancer Rsrch, Jiangsu, China[13]Tangdu Hospital, Fourth Military Medical University, Xi'an, China[14]The Affiliated Tumor Hospital of Harbin Medical University, Harbin, Heilong Jiang Province, China[15]Department of Medical Oncology, Cancer Institute and Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, Beijing, China[16]Department of Medical Oncology, Cancer Institute/Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College[17]Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, Beijing, China[18]Peking University Clinical Research Institute, Beijing, China[19]Nanjing Military General Hospital, Nanjing, China[20]Beijing Chest Hospital, Capital Medical University, Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing, China[21]Betta Pharmaceuticals Co.,Ltd., Hangzhou, China[22]The 1st Affiliated Hospital, Hangzhou, China
第一作者机构：[1]Department of Medical Oncology, Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College[2]Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, Beijing, China[3]Department of Medical Oncology, Cancer Institute/Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China[4]Shanghai Chest Hospital, Shanghai, China[5]First Hospital Affiliated to Jilin University, Jilin, China[6]Department of Lung Cancer Medical Oncology, Sichuan Cancer Hospital, Chengdu, China[7]Department of Medical Oncology, the First Hospital of China Medical University, Shenyang, China[8]Tumor Hospital Of Hebei Province, Shijiazhuang, China[9]Shanxi Provincial Tumor Hospital, Taiyuan, China[10]Henan Cancer Hospital, Zhengzhou, China[11]Xijing Hospital, Xian, China[12]China Jinagsu Province Inst of Cancer Rsrch, Jiangsu, China[13]Tangdu Hospital, Fourth Military Medical University, Xi'an, China[14]The Affiliated Tumor Hospital of Harbin Medical University, Harbin, Heilong Jiang Province, China[15]Department of Medical Oncology, Cancer Institute and Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, Beijing, China[16]Department of Medical Oncology, Cancer Institute/Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College[17]Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, Beijing, China[18]Peking University Clinical Research Institute, Beijing, China[19]Nanjing Military General Hospital, Nanjing, China[20]Beijing Chest Hospital, Capital Medical University, Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing, China[21]Betta Pharmaceuticals Co.,Ltd., Hangzhou, China[22]The 1st Affiliated Hospital, Hangzhou, China
推荐引用方式(GB/T 7714)：
Shi Yuankai,Wang Lin,Han Baohui,et al.First-line icotinib versus cisplatine/pemetrexed plus pemetrexed maintenance therapy in lung adenocarcinoma patients with sensitizing EGFR mutation (CONVINCE).[J].JOURNAL OF CLINICAL ONCOLOGY.2016,34(15):doi:10.1200/JCO.2016.34.15_suppl.9041.
APA：
Shi, Yuankai,Wang, Lin,Han, Baohui,Li, Wei,Yu, Ping...&Tan, Fenlai.(2016).First-line icotinib versus cisplatine/pemetrexed plus pemetrexed maintenance therapy in lung adenocarcinoma patients with sensitizing EGFR mutation (CONVINCE)..JOURNAL OF CLINICAL ONCOLOGY,34,(15)
MLA：
Shi, Yuankai,et al."First-line icotinib versus cisplatine/pemetrexed plus pemetrexed maintenance therapy in lung adenocarcinoma patients with sensitizing EGFR mutation (CONVINCE).".JOURNAL OF CLINICAL ONCOLOGY 34..15(2016)
医学